UroGen Pharma Stock
UroGen Pharma Ltd.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Elizabeth Barrett
- Employees
- 300
- Market cap
- $1.7 B
- IPO
- 04/05/2017
UroGen Pharma Ltd. is a biotechnology company in the healthcare sector, headquartered in Princeton, New Jersey. The company engages in the development and commercialization of solutions for urothelial and specialty cancers. Its product portfolio includes RTGel, a novel proprietary polymeric biocompatible, reverse…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
UroGen Pharma stock: price history
1D
-5.6%
1W
-6.2%
1M
-20.5%
6M
+53.3%
YTD
+47.6%
1Y
+104.1%
2Y
+174.3%
5Y
+103.1%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~19% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
UroGen Pharma stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
UroGen Pharma is a biotechnology company specializing in the development and commercialization of therapies for urothelial carcinoma. Current revenue business is entirely driven by sales of the product Jelmyto. The company leverages proprietary hydrogel technology and has several drug candidates in advanced Phase 3 clinical trials to expand its portfolio for the treatment of bladder cancer. Additionally, the company is working with partners such as Agenus Inc. and medac Gesellschaft für klinische Spezialpräparate m.b.H. through licensing and supply agreements on the development of new solutions.
- Revenue model
- Transactional
- Recurring revenue
- None
- Pricing power
- Strong
- Moat
- Wide
- Moat type
- Switching costs
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about UroGen Pharma
Analyst assessment of UroGen Pharma
PRICE TARGET LOW
US$44.00
CONSENSUS
US$56.60
MEDIAN
US$56.00
PRICE TARGET HIGH
US$75.00
0
STRONG BUY
12
BUY
4
HOLD
0
SELL
0
STRONG SELL
16
TOTAL · Buy
As of: 06/08/2026
UroGen Pharma stock metrics
P/E
-17.45
P/B
-13.15
EV/EBITDA
-25.76
RETURN ON EQUITY
10.8%
NET MARGIN
-19.8%
DEBT/EQUITY
-1.48
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
88.8%
FLOAT SHARES
43,407,407
AVG. DAILY VOLUME (30D)
915,281
Insider transactions (SEC)
Degnan Chris
Degnan Chris
Smith Jason Drew
Schoenberg Mark
Schoenberg Mark
Institutional holders
Comparable stocks
Frequently asked questions about UroGen Pharma stock
What does UroGen Pharma do?
UroGen Pharma Ltd. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Elizabeth Barrett, the company employs around 300 people.
The IPO was on 04/05/2017; the stock trades on NASDAQ under the ticker URGN.
What do analysts say about UroGen Pharma stock?
16 analysts rate the stock, the consensus is Buy (as of 06/08/2026).
The average price target is US$56.60, ranging from US$44.00 to US$75.00, with a median of US$56.00.
This is an external assessment, not a statement by Market Jury.
When does UroGen Pharma report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 19% stronger than usual.
Does UroGen Pharma pay a dividend?
No, UroGen Pharma currently does not pay a dividend.
Which stocks are comparable to UroGen Pharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get UroGen Pharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess UroGen Pharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.